Immix Biopharma Reports $21.6 Million Net Loss and Significant Asset Growth in Latest 10-Q Filing

Immix Biopharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $21.6 million for the first half of 2026, compared to a loss of $11.2 million during the same period in 2025. This increase in losses is attributed primarily to higher general and administrative expenses, which rose to $11.9 million from $5.5 million year-over-year, driven by increased staffing and related costs. Research and development expenses also increased to $11.3 million from $5.9 million, reflecting ongoing clinical trials and related activities.

The company’s total assets surged to approximately $239.1 million as of June 30, 2026, up from $104.8 million at the end of 2025. This increase was largely due to successful capital raises, including a public offering in May 2026 that generated net proceeds of approximately $140.7 million. Immix Biopharma's cash, cash equivalents, and short-term investments totaled about $232.1 million, providing a solid liquidity position to support ongoing operations and clinical trials.

Operationally, Immix Biopharma is advancing its lead candidate, CAR-T NXC-201, which is currently in a Phase 1b/2 clinical trial for the treatment of relapsed/refractory AL Amyloidosis. The company has reported promising interim results, including a 95% complete response rate among patients treated. The FDA has granted Breakthrough Therapy designation for NXC-201, which is expected to expedite its development and review process. The company plans to initiate a Phase 3 trial for newly diagnosed patients in the near future.

In terms of strategic developments, Immix Biopharma has been actively expanding its funding sources. The company received an $8 million grant from the California Institute for Regenerative Medicine to support its clinical development efforts. Additionally, it has entered into an At The Market Offering Agreement, allowing it to sell shares of common stock to raise further capital as needed. As of June 30, 2026, the company had sold a total of 3.2 million shares under this agreement, generating net proceeds of approximately $18.4 million.

Looking ahead, Immix Biopharma anticipates continued operating losses as it invests heavily in research and development to advance its clinical programs. The company is focused on securing additional funding to support its operations beyond the next 12 months, as it aims to bring its innovative therapies to market. The management remains optimistic about the potential of its product candidates and the strategic partnerships that may arise as it progresses through clinical trials.